Bionano Genomics (BNGO) Income from Continuing Operations (2017 - 2026)

Bionano Genomics has disclosed Income from Continuing Operations across 10 years of filings, most recently posting 8303000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 8303000.0, down 167.67% year-over-year; the trailing twelve-month figure through Mar 2026 was 31596000.0 (up 62.45% YoY), and the FY2025 annual result was 26395000.0, up 76.53% from the prior year.
• Income from Continuing Operations came in at 8303000.0 for Q1 2026 at Bionano Genomics, down from 7933000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 3102000.0 in Q1 2025 to a low of 112566000.0 in Q3 2023.
• The 5-year median for Income from Continuing Operations is 31422000.0 (2024), against an average of 30131882.35.
• Across the five-year window, Income from Continuing Operations sank 253.88% in 2023 and surged 90.13% in 2025, its largest moves.
• Bionano Genomics' Income from Continuing Operations stood at 38677000.0 in 2022, then retreated by 13.48% to 43891000.0 in 2023, then surged by 53.15% to 20563000.0 in 2024, then jumped by 61.42% to 7933000.0 in 2025, then slipped by 4.66% to 8303000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 8303000.0 (Q1 2026), 7933000.0 (Q4 2025), and 8503000.0 (Q3 2025), per Business Quant data.